Fig. 7From: Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trialsComparison of efficacy and safety outcomes between 100 mg and 300 mg eptinezumab. a: monthly migraine days (MMDs); b: 75% responder rate; c: 50% responder rate; d: patients with migraine 1 day after dosing; e: treatment emergent adverse events (TEAEs)Back to article page